Adherence and Access Challenges

Panelists discuss how medication access, affordability, and complex insurance processes present major barriers for patients with tardive dyskinesia (TD). The high cost of VMAT2 inhibitors can hinder consistent use, leading to relapse of symptoms.

Panelists discuss how pharmacists assist by navigating prior authorizations, identifying co-pay assistance programs, and working with patient support services to ensure continuous therapy. Their proactive role often determines whether patients remain adherent or lapse in care.

Panelists discuss how simplifying regimens, reinforcing education, and addressing financial barriers collectively enhance long-term adherence. The pharmacist’s advocacy ensures equitable access and sustained benefit from treatment.